Maarten Lansberg, MD
Vascular Neurology · Stanford, CANPI 1275690430
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,690 of the $85,962 with a category attached, or 97.4%. Genentech, Inc. accounts for 95.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $43,805 and has fallen 53.5% since, to $20,355 in 2023. Among vascular neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $8596.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$82K
- Novo Nordisk AS$2K
- F. Hoffmann-la Roche AG$2K
- Viz.ai, Inc.$335
Across 5 payments — averaging $6863.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$32K
- F. Hoffmann-la Roche AG$2K
- Novo Nordisk AS$200
What the payments were for
- Consulting fees$83,69097%
- Speaking & faculty fees$1,7672%
- Food & beverage$5051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 4 | $81,820 |
| Novo Nordisk AS | 1 | $2,040 |
| F. Hoffmann-la Roche AG | 4 | $1,767 |
| Viz.ai, Inc. | 1 | $335 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Activase$63,062
- TNKase$63,062
- Cathflo Activase$61,295
- Viz.AI LVO$335
How this compares
$85,962 in reported general payments places this provider in the 90th percentile of 58 vascular neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cilostazol | 16 | $847 |
| Amlodipine Besylate | 15 | $118 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Stanford
- Gregory AlbersStanford$415K
- Chitra VenkatasubramanianStanford$260K
- Sarah LeeStanford$35K
- Nirali VoraStanford$5K
- Neeharika KrothapalliStanford$959
- Lironn KralerStanford$20
- Shuichi SuzukiArcadia$126K
- Royya ModirSan Diego$113K
- Muhammad TaqiPalm Springs$77K
- Ashish NandaFullerton$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.